

bsm-54138R**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

JAK1 Recombinant Rabbit mAb**— DATASHEET —**


Host: Rabbit	Isotype: IgG	Applications: WB (1:200-1000)
Clonality: Recombinant	CloneNo.: 2B12	IHC-P (1:100-500)
GeneID: 3716	SWISS: P23458	IHC-F (1:100-500)
Target: JAK1		IF (1:100-500)
Immunogen: A synthesized peptide derived from human JAK1: 625-660.		Reactivity: Human, Mouse, Rat
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		Predicted MW.: 133 kDa
Background: Janus kinase 1 (JAK1) is a member of a new class of non-receptor protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The second phosphotransferase domain bears all the hallmarks of a protein kinase, although its structure differs significantly from that of the PTK and threonine/serine kinase family members. JAK1 is a large, widely expressed membrane-associated phosphoprotein. It is involved in the interferon-alpha/beta and -gamma signal transduction pathways. The reciprocal interdependence between JAK1 and TYK2 activities in the interferon-alpha pathway, and between JAK1 and JAK2 in the interferon-gamma pathway, may reflect a requirement for these kinases in the correct assembly of interferon receptor complexes. These kinases couple cytokine ligand binding to tyrosine phosphorylation of various known signaling proteins and a unique family of transcription factors termed the signal transducers and activators of transcription, or STATs.		Subcellular Location: Cytoplasm

— VALIDATION IMAGES —

25 ug total protein per lane of various lysates (see on figure) probed with JAK1 monoclonal antibody, unconjugated (bsm-54138R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with JAK1 Monoclonal Antibody, Unconjugated(bsm-54138R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Cervical Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with JAK1 Monoclonal Antibody, Unconjugated(bsm-54138R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.

— SELECTED CITATIONS —

- **[IF=17.4]** Hui Yan. et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment. NANO TODAY. 2024 Apr;55:102220 WB ;Mouse. 10.1016/j.nantod.2024.102220
- **[IF=7.5]** Junchao Wu. et al. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis. BIOMED PHARMACOTHER. 2024 Feb;171:116167 WB,IHC ;Mouse. 38262152
- **[IF=2.5]** Jie Luo. et al. Xin Sheng Hua Granule ameliorate chemotherapy-induced blood deficiency syndrome through

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

inhibiting JAK1/STAT1 pathway activation. FITOTERAPIA. 2025 Jun;183:106571 IHC,WB ;Mouse. 40316148